Since blood transfusions are needed worldwide, the blood transfusion diagnostics industry is growing. Many factors contribute to the growth in blood transfusions. Surgical operations, trauma, and anemia are examples. This issue has driven demand for diagnostic equipment and testing.
The blood screening sector has been greatly impacted by technological advances. Blood transfusion diagnoses are improved by sophisticated screening technologies including nucleic acid testing (NAT) and enhanced immunoassays. This is done to fulfill the growing need for safe, trustworthy blood products.
The market is affected by strict blood safety and transfusion diagnostics regulations. This is the result of constraints. Since regulatory organizations worldwide have set strict standards for screening given blood for infectious illnesses, the usage of modern diagnostic methods that meet these requirements has increased.
Blood-donating organizations must undergo extensive screening due to the presence of blood-borne infections including HIV, hepatitis, and others. Diagnostics for blood transfusions are crucial because they identify and eliminate tainted blood units. This shields blood donors and receivers from health dangers.
The market is growing due to increased awareness of safe blood transfusions and diagnostics' role in blood safety. This understanding helps keep blood safe. Healthcare institutions and government organizations are promoting transfusion diagnostic technology via education. Healthcare facilities run these programs.
Blood supply problems, exacerbated by natural catastrophes and public health issues, highlight the need for effective and efficient blood transfusion diagnostics. Diagnostic tools that assure safe blood product availability amid shortages are growing in popularity. These technologies accelerate screening.
Diagnostic technologies in healthcare systems are a major market driver. Automated and integrated transfusion diagnostics systems help hospitals and blood banks streamline blood transfusion services and testing. These systems improve testing efficiency.
The amount of blood given is rising worldwide due to voluntary blood donation campaigns. Effective, high-throughput blood transfusion diagnostics will be needed as donor numbers grow. This will boost market growth.
International blood transfusion disease control methods are changing the business world. WHO is leading blood safety programs. Healthcare institutions must invest in advanced transfusion diagnostics to screen effectively, according to the WHO. WHO leads these activities.
The COVID-19 pandemic has affected the Blood Transfusion Diagnostics Market by highlighting the necessity for a robust and secure blood supply chain. Modern diagnoses have been hastened due to pandemic measures and screening. These procedures protect blood donors and recipients.
Study objectives: Main objective of this research is to provide information about Blood Transfusion Diagnostics market, product, technology and end users.
Key Players
Grifols (Spain), Thermo Fisher Scientific, Inc. (U.S.), Roche Diagnostics (Switzerland), bioMérieux (France), Bio-Rad Laboratories, Inc. (U.S.), Immucor (U.S), Siemens Healthineers (Germany), Ortho Clinical Diagnostics, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Novartis AG (Switzerland), Beckman Coulter, Inc. (U.S.), Ortho Clinical Diagnostics (U.S), Beckman Coulter (U.S), Diagast (France), Abbott Diagnostics (U.S), BAG healthcare (Germany), DiaSorin (Italy), Fujirebio (Belgium), Grifols (Spain), Quidel (U.S), Hologic/Gen-Probe (U.S), Biokit (Spain).
The report for Blood Transfusion Diagnostics market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Blood Transfusion Diagnostics market has been segmented on the basis of blood product including Red Blood Cells, Platelets, Plasma, Albumin, Immunoglobulin Preparations and other products. On the basis of technology, the market is segmented into Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test and other technologies. ELISA is further segmented into chemiluminescence immunoassay (CLIA), fluorescence immunoassays (FIA), and colorimetric immunoassay (CI). Nucleic Acid Amplification is segmented into Thermomechanical analysis (TMA) and real-time PCR. End users are hospitals, clinics, blood banks, laboratories.
Globally, Blood Transfusion Diagnostics market consists of four regions Americas, Europe, Asia Pacific and Middle East and Africa. America is the largest market whose growth is attributed to an increase in the use of nucleic acid amplification test and large number of awareness programs conducted by the government bodies and non-government organizations. Europe is the second largest market. Asia Pacific is showing positive growth this market. The market shows steady growth in Middle East & Africa.
Recent Development
Ortho Clinical Diagnostics introduced the ORTHO VISION Swift and ORTHO VISION Max Swift analyzers in April 2021. These analyzers provide laboratory networks with more processing power and enhanced data security. Hemanext, a blood storage technology company, said in September 2021 that it would raise USD 15 million in a new series A fundraising round and USD 100 million from private equity. Its goal is to spread the Hemanext One System's processes all over the world. The technology has a CE designation, which means it can be sold throughout Europe.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)